Nicox

en fr

About Us
Pipeline, Markets and Science
Investors
News and Events
Contact Us

Nicox announces that its Exclusive Licensee Submits response to CRL for latanoprostene bunod ophthalmic solution, 0.024%

August 18, 2017

← Back to blog page

Nicox

Contact Us
Subscribe to news
Legal Notice

Search

© Copyright Nicox, all rights reserved

Cookies

By continuing to use this website, you agree to our Cookie Policy.